证券日报网讯2月25日，乐心医疗（300562）在互动平台回答投资者提问时表示，截至2026年2月13日， 公司股东总户数为23363户。 ...

近7个交易日(2026年2月6日至2月13日)，乐心医疗股价区间波动较为明显。截至2月13日收盘，股价报 14.65元，较2月6日收盘价14.62元微涨0.21%，但期间振幅达5.75%，最高价为2月11日的15.03元。资金 流向方面，2月11日主力资金净流出445.88万元，而游资资金净流入493.87万元，显示短期资金分歧。从 技术面看，当前股价位于20日布林线中轨附近(约14.865元)，短期支撑位在14.34元，压力位在15.39元。 经济观察网乐心医疗（300562）在投资者互动平台表示，公司开发的大模型应用已正式上线，主要聚焦 于心脑血管疾病风险评估功能，并已完成相关试点，试点效果良好。公司强调尚无法预测该业务对未来 业绩的具体影响，并提醒投资者注意风险。这一进展体现了公司在AI数字慢病管理领域的创新布局， 可能对市场情绪产生积极影响。 股票近期走势 以上内容基于公开资料整理，不构成投资建议。 ...

Group 1 - The core viewpoint of the article is that Lexin Medical is focusing on overseas markets for its business development in the next 1-2 years, aligning with its strategic direction and growth potential [2] - The company defines the second industry curve as related businesses that align with its strategic development direction and have greater growth potential [2] Group 2 - The company is currently positioning itself based on its strategic planning, indicating a clear focus on international expansion [2] - The response to investor inquiries highlights the company's commitment to its strategic goals and future business planning [2]

Core Viewpoint - The company has made progress in developing a large model application focused on cardiovascular diseases, which includes risk assessment capabilities and has undergone successful pilot testing [2] Group 1 - The large model application is primarily aimed at cardiovascular disease [2] - The application has been launched and has completed relevant pilot tests with positive results [2] - The company is unable to predict the future impact of this business on its performance [2]

Core Viewpoint - The company, Lexin Medical, has indicated that its smart ring product will not be launched in the consumer market before the Spring Festival due to ongoing software development and iteration processes [2] Group 1: Product Development - The software related to the smart ring is still under development and iteration [2] - The company will determine the launch timing based on internal business planning and external market conditions [2] - Specific details regarding the product launch will be announced in future communications [2]

Core Viewpoint - Le Xin Medical (300562.SZ) is focusing on digital chronic disease management solutions in European and American markets, offering products such as smart blood pressure monitors and smart blood glucose meters [2] Group 1 - The company's current business in Europe and the United States primarily revolves around Remote Patient Monitoring (RPM) solutions [2]

Core Viewpoint - Lexin Medical (300562.SZ) is focusing on developing a multi-dimensional physiological monitoring product line that enables high-precision data collection and transmission [1] Group 1: Product Development - The company has developed a large model application in the vertical field of cardiovascular diseases [1] - Lexin Medical plans to integrate this application with its medical-grade health monitoring products [1] Group 2: Service Offering - The company aims to provide a comprehensive chronic disease management solution that includes "medical-grade smart monitoring devices + data analysis + medical health services" [1] Group 3: Future Performance - The company is currently unable to predict the impact of these related businesses on its future performance [1]

Core Viewpoint - The aging population is driving the growth of the silver economy, and the company aims to leverage its product matrix to provide comprehensive health monitoring for the elderly [1] Group 1: Company Strategy - The company currently offers a range of health monitoring products, including blood pressure, blood sugar, body fat, and heart rate monitoring for the elderly [1] - The company plans to actively seek relevant partnerships to capitalize on its existing business advantages and explore new emerging cooperation models [1] Group 2: Market Outlook - The company is unable to predict the impact of future business developments, indicating uncertainty in the market environment [1]

Group 1 - The core viewpoint of the article highlights that despite the significant contribution of overseas markets to the company's revenue and rapid profit growth, the stock price of the company has remained stagnant for several years [1] - The company acknowledges the impact of macroeconomic factors and market sentiment on its stock price performance, indicating that it is committed to improving operational management and enhancing communication with the market to better convey its investment value [1] - The company has achieved steady profit growth through strategic upgrades and optimization of its business structure, reflecting its efforts to adapt and thrive in the competitive medical industry [1]

Core Viewpoint - The financial performance of Loxin Medical (300562) shows a slight increase in revenue and a significant rise in net profit for the first three quarters of 2025, indicating potential growth in the home medical equipment and remote health management sectors [2]. Financial Performance Summary - For the first three quarters of 2025, Loxin Medical reported a main revenue of 757 million yuan, a year-on-year increase of 0.1% [2]. - The net profit attributable to shareholders reached 65.68 million yuan, reflecting a year-on-year increase of 29.99% [2]. - The net profit after deducting non-recurring items was 59.62 million yuan, up by 19.35% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 236 million yuan, a decrease of 8.53% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 23.39 million yuan, showing a significant increase of 49.2% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was 21.55 million yuan, up by 22.64% year-on-year [2]. - The company's debt ratio stands at 30.1%, with investment income of 4.33 million yuan and financial expenses of 2.01 million yuan [2]. - The gross profit margin is reported at 35.59% [2]. Market Activity Summary - As of February 10, 2026, Loxin Medical's stock closed at 14.88 yuan, with an increase of 0.47% [1]. - The turnover rate was 3.46%, with a trading volume of 56,000 hands and a transaction amount of 83.32 million yuan [1]. - On February 10, the net outflow of main funds was 9.36 million yuan, accounting for 11.23% of the total transaction amount [1]. - The net inflow of retail funds was 2.34 million yuan, representing 2.81% of the total transaction amount [1]. - The net inflow of speculative funds was 7.01 million yuan, making up 8.42% of the total transaction amount [1].